OpenURL Connection Search

Select item for more details and to access through your institution.

An intact C-terminal end of albumin is required for its long half-life in humans.
Published in:
Communications Biology, 2020, v. 3, n. 1, p. 1, doi. 10.1038/s42003-020-0903-7
By:
- Nilsen, Jeannette;
- Trabjerg, Esben;
- Grevys, Algirdas;
- Azevedo, Claudia;
- Brennan, Stephen O.;
- Stensland, Maria;
- Wilson, John;
- Sand, Kine Marita Knudsen;
- Bern, Malin;
- Dalhus, Bjørn;
- Roopenian, Derry C.;
- Sandlie, Inger;
- Rand, Kasper Dyrberg;
- Andersen, Jan Terje
Publication type:
Article
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules.
Published in:
Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-03061-x
By:
- Grevys, Algirdas;
- Nilsen, Jeannette;
- Sand, Kine M. K.;
- Daba, Muluneh B.;
- Øynebråten, Inger;
- Bern, Malin;
- McAdam, Martin B.;
- Foss, Stian;
- Schlothauer, Tilman;
- Michaelsen, Terje E.;
- Christianson, Gregory J.;
- Roopenian, Derry C.;
- Blumberg, Richard S.;
- Sandlie, Inger;
- Andersen, Jan Terje
Publication type:
Article
Human and mouse albumin bind their respective neonatal Fc receptors differently.
Published in:
Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-32817-0
By:
- Nilsen, Jeannette;
- Bern, Malin;
- Sand, Kine Marita Knudsen;
- Grevys, Algirdas;
- Dalhus, Bjørn;
- Sandlie, Inger;
- Andersen, Jan Terje
Publication type:
Article
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics.
Published in:
Science Translational Medicine, 2020, v. 12, n. 565, p. 1, doi. 10.1126/scitranslmed.abb0580
By:
- Bern, Malin;
- Nilsen, Jeannette;
- Ferrarese, Mattia;
- Sand, Kine M. K.;
- Gjølberg, Torleif T.;
- Lode, Heidrun E.;
- Davidson, Robert J.;
- Camire, Rodney M.;
- Bækkevold, Espen S.;
- Foss, Stian;
- Grevys, Algirdas;
- Dalhus, Bjørn;
- Wilson, John;
- Høydahl, Lene S.;
- Christianson, Gregory J.;
- Roopenian, Derry C.;
- Schlothauer, Tilman;
- Michaelsen, Terje E.;
- Moe, Morten C.;
- Lombardi, Silvia
Publication type:
Article
Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life.
Published in:
Communications Biology, 2022, v. 5, n. 1, p. 1, doi. 10.1038/s42003-022-03787-x
By:
- Gjølberg, Torleif Tollefsrud;
- Frick, Rahel;
- Mester, Simone;
- Foss, Stian;
- Grevys, Algirdas;
- Høydahl, Lene Støkken;
- Jørstad, Øystein Kalsnes;
- Schlothauer, Tilman;
- Sandlie, Inger;
- Moe, Morten C.;
- Andersen, Jan Terje
Publication type:
Article

Found: 5

An intact C-terminal end of albumin is required for its long half-life in humans.

A human endothelial cell-based recycling assay for screening of FcRn targeted molecules.

Human and mouse albumin bind their respective neonatal Fc receptors differently.

An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics.

Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life.